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Oxidative damage to the genome can form 8-oxoguanine (oxoG), a premutagenic lesion            
suggested to play an epigenetic role in the regulation of various cellular pathways.             
Alongside oxoG in this regulation is the 8-oxoguanine DNA glycosylase (OGG1), which            
primarily functions to repair oxoG damage via base excision repair, but is also             
implicated in recruiting NFκB and impacting gene expression associated with cancer           
growth. This proposal aims to build genome-wide maps of oxoG occupancy, and            
indirectly OGG1 localization, in healthy lung cells and in non-small cell lung cancer             
adenocarcinoma cells in order to identify regulatory regions in the genome at which             
oxoG is prevalent at higher rates in cancer cells relative to healthy cells. Measuring the               
occupancy of oxoG will be accomplished using two relatively new methods known as             
OG-seq and enTRAP-seq, both of which improved upon the resolution, throughput, and            
the scope of previous mapping techniques. The transcriptional changes resulting from           
increased oxoG/OGG1 occupancy will be quantified using Real Time qRT-PCR. The           
results of these experiments will aid in characterizing the roles of oxoG and OGG1 in               
regulation of transcription associated with cancer growth and can inform effective           




A. Specific Aims  
This proposal will develop genome-wide maps of oxoG and OGG1 using the            
established OG-seq and enTRAP-seq methods in healthy human lung cells and in            
cancerous human lung cells. These maps will enable detection of significant differences            
in localization of oxoG between the cell types and can reveal correlations between the              
cancer phenotype and certain genes and their associated regulatory regions. Once           
identified, the expression of those genes will be investigated to further understand their             
relationship with oxoG, OGG1, and the proliferation of cancer cells. Inhibiting OGG1            
while measuring changes in gene expression will aid in confirming that any alterations in              
expression are in fact associated with OGG1 occupancy and not as a result of some               
other source. 
1. Identify differences in oxoG enrichment in both quantity and location in the 
genome between healthy and cancerous lung cells. 
a. Genome-wide mapping of oxoG using OG-seq 
b. Genome-wide mapping of oxoG using enTRAP-seq 
2. Investigate if oxoG enrichment and OGG1 occupancy are associated with 
the changes in expression level of key genes in both healthy lung epithelial 
cells and lung cancer cells. 
a. Healthy vs cancer 





B. Background and Significance 
I. OGG1 as a DNA Glycosylase 
One of the most prominent forms of DNA damage comes in the form of oxidative               
damage inflicted on the genetic material by reactive oxygen species (ROS). Such            
damage contributes to the development of a myriad of degenerative diseases as the             
accumulation of oxidative damage takes a toll on the genomic integrity of the organism.              
Cardiovascular diseases, immune deficiencies, and cancerous cell growth can be tied to            
the store of mutations that result from the onslaught of both endogenous ROS from              
metabolism and exogenous ROS from UV radiation, pollution, and other sources.​1,2           
Guanine serves as an electron rich target for these oxidative species, producing the             
mutagenic lesion 8-oxoguanine (oxoG). In this mutagenic form, oxoG can incorrectly           
base pair with an adenine base during replication at an equal rate to the correct               
cytosine pairing (oxoG:C).​3 This incorrect adenine pairing (oxoG:A) can result in a G:C             
to T:A mutation after two cycles of replication if not properly repaired. Thus, an efficient               
repair pathway is necessary to excise the damaged base before replication turns the             
mutagenic lesion into an undetectable mutation. 
 
Figure 1. Oxidative stress in the form of ROS oxidize guanine to produce the mutagenic lesion                
8-oxoguanine (oxoG). 8-oxoguanine DNA glycosylase (OGG1) excises the damaged base to produce an             




The Base Excision Repair (BER) Pathway performs that precise repair action beginning            
with the removal of the damaged base using a DNA glycosylase, producing an apurinic              
site in the DNA (Figure 1) that is subsequently excised by an AP endonuclease (APE),               
and replaced by a DNA polymerase (DNAP) and ligase.​4–7 Specific to the oxoG lesion,              
8-oxoguanine DNA glycosylase 1 (OGG1) functions as the initial repair protein that            
begins the BER pathway to correct this damage. OGG1 has been shown to only remove               
oxoG bases that are opposite a cytosine. Removing an oxoG that has incorrectly             
base-paired with an adenine would only guarantee the mutation will occur, as the             
machinery would identify an unpaired A and insert a T opposite, cementing the G:C to               
T:A transversion. To prevent this, an enzyme known as MutY in bacteria and MUTYH in               
humans removes any adenines paired with an oxoG to revert to an oxoG:C pairing that               
can be treated by OGG1.​4,7 
II. OGG1 as a Regulatory Element 
While the pivotal role OGG1 plays in the maintenance of genomic integrity is well              
documented, recent studies have implicated human OGG1 (hOGG1) in a number of            
auxiliary pathways including the proinflammatory response pathway and innate immune          
responses.​8–10 Further investigations have pointed to the oxoG lesion serving as an            
epigenetic marker that specifically regulates gene expression driven by Nuclear          
Factor-κB (NFκB), a key transcription factor associated with cell viability, cytokine           
production, and immune response.​9,11 This makes OGG1 a promising candidate for           
therapeutic development in a number of disease pathologies and its potential role in             
cancer treatment is already being unveiled. 
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Nuclear Factor-κB (NFκB) can be activated by tumor necrosis factor alpha (TNFɑ), an             
inflammatory cytokine produced by immune cells during acute inflammation that enacts           
a myriad of signalling events within cells leading to necrosis or apoptosis.​12,13 As NFκB              
is implicated in the biological defense against tumorigenesis, among other diseases, its            
mechanistic integration with OGG1 points to OGG1 serving as a downstream target            
and/or an upstream initiator in innate immune pathways.​14–17 Oxidative stress induced           
by the proinflammatory response of TNFɑ and NFκB to combat infection or tumor             
growth causes reversible oxidation of the cysteine residues in OGG1, inhibiting the base             
excision function without compromising the enzyme’s ability to bind to the DNA and flip              
the damaged base out of the helix.​18,19 This transient stalling is what enables OGG1 to               
recruit transcription factors such as NFκB directly to the chromatin in order to induce              
gene expression.​9,11,19,20 The proposed mechanism hypothesizes that oxidative stress         
recruits OGG1, then stalls OGG1 before repair in order to facilitate recruitment of             




Figure 2. Oxidative stalling model presented by Vlahopoulos and colleagues.​19 Signals from TNFɑ induce              
oxidative stress and produce oxoG, initiating OGG1 occupancy at the damaged lesion. Remaining             
oxidative stress prevents immediate repair by temporarily oxidizing key cysteine residues in OGG1,             
allowing for localization of NFκB and subsequent gene expression. When the oxidation is reversed, the               
stalling ceases and the base excision repair (BER) pathway is completed. 
 
III. OGG1 Inhibition in Cancer Treatment 
Synthetic inhibitors of OGG1 were shown to decrease occupancy of NFκB on DNA             
containing oxoG in cells exposed to TNFɑ and the resultant oxidative stress.​21 Seeing             
that OGG1 may be deeply woven into cancer growth and the biological response,             
investigations into its potential as a therapeutic target are well warranted. Inhibition of             
OGG1 has potential to serve as a co-chemotherapeutic treatment in order to weaken             
the ability of targeted tumors to repair DNA under assault by chemotherapeutic agents.             
However, upregulation of OGG1 can be a potential preemptive or even early stage             
treatment method of enhancing the apoptotic pathway of TNFɑ and NFκB in hampering             
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tumorigenesis. Because oxoG may be serving as an epigenetic marker in cancer            
growth, a genomic map of these damaged guanines can serve as a guide as to whether                
these epigenetic markers are regulated by location: whether they are most prominently            
found in promoters, enhancers, or within the genes themselves. Both ​in vitro ​and ​in vivo               
studies found significantly higher levels of oxoG in open chromatin and regulatory            
elements, specifically in 5’ untranslated regions (5’UTRs), promoter regions, and CpG           
islands, relative to an expected random dispersion of damage across the genome.​22–25            
This is a promising indication that the enrichment of the oxidative damage is not              
randomly distributed, but is connected to regulatory mechanisms beyond simple          
damage-repair pathways. In part, this proposal aims to identify if the regulatory regions             
with higher incidence of oxoG lesions are connected to established proto-oncogenes           
and/or tumor suppressor genes. If such enrichment is uncovered, the implications of            
OGG1 in cancer treatment would be greatly expanded. 
There are two primary methods for developing a genome-wide map of oxoG damage:             
OG-seq​22 and enTRAP-seq​23​. OG-seq labels the oxoG damage sites with biotin in order             
to enable affinity purification, replacing the previous standard of immunoprecipitation as           
the means of quantifying enrichment and identifying genomic location. On the other            
hand, enTRAP-seq uses an OGG1 with a K249Q point mutation to freeze the             
glycosylase at the oxoG damage without repairing it and without compromising           
substrate recognition. This mutation used in enTRAP-seq replicates the effect of the ​in             
vitro borohydride trapping reaction - which creates a covalent intermediate between           
oxoG and OGG1 - and the trapped complexes can also be precipitated using affinity              
purification.​23 Both of these methods will be valuable in identifying where the oxidation             
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occurs across the genome, indicating loci at which OGG1 engages with the genome             
and possibly recruits NFκB. 
While these initial studies have expanded the possibilities of genome mapping and            
deepened the understanding of the epigenetic role of oxoG and OGG1, this proposal             
intends to dig into the specific genes impacted to determine any salient correlation             
between this damage-turned-signal and cancer growth. Additionally, the impact of          
OGG1 inhibitors on the expression of the genes of interest will be investigated as a               
manner of validating the reliance of the target gene expression on OGG1 occupancy, as              
well as the potential to take advantage of those findings in therapeutic development. 
C. Research Design and Methods 
The long term objective of this project is to understand if the proposed mechanistic              
interactions between OGG1, TNFɑ, and NFκB in gene regulation bears any significance            
in oncological therapeutic development. This proposal is distinct from the studies that            
established the methods that will be used for two primary reasons. First, as the broader               
goals of this investigation are tied to cancer, human lung cells will be used as opposed                
to the mouse embryonic fibroblasts in which these methods were developed.           
Non-cancerous cells will be from the BEAS-2B cell line (human lung epithelial cells) and              
the cancerous cells will be from the NCI-H1563 line (adenocarcinoma, non-small cell            
lung cancer) or the NCI-H1838 line (adenocarcinoma, non-small cell lung cancer). Each            
of these cultures will be grown under identical conditions. Second, these experiments            
seek to integrate these methods with an investigation into the relationship between            
oxoG, OGG1, cancer, and the resultant changes in gene expression. The previous            
studies were each isolated uses of the genome-wide mapping techniques and this            
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proposal intends to utilize the techniques to address the nature of the relationship             
between each of these elements. 
The experiments proposed here will study the epigenetic behavior of the genomic            
8-oxoguanine residue (oxoG) and the role of the glycosylase OGG1 as a regulatory             
element. As this epigenetic mechanism may be intrinsically tied to tumorigenesis and            
anticancer response pathways, identifying the implicated genes as proto-oncogenes or          
tumor suppressor genes will inform the prospects of OGG1 serving as a therapeutic             
target. Changes in gene expression between healthy cells, cancer cells, and cancer            
cells exposed to OGG1 inhibitors will further inform those prospects and uncover the             
relationship between TNFɑ, NFκB, and OGG1. 
Aim 1: Identify genome-wide differences in oxoG enrichment between healthy and 
cancerous lung cells. 
a. Genome-wide mapping of oxoG using OG-seq 
b. Genome-wide mapping of oxoG using enTRAP-seq 
Objective and Overview: We will establish the presence of any basal difference between             
the amount and location of oxoG damage in healthy and cancerous cells. This will be               
achieved by specifically mapping oxoG damage using both the OG-seq method and the             
enTRAP-seq method. Genomic localization of OGG1 is expected to match oxoG           
enrichment, which can be confirmed using ChIP-seq with anti-OGG1 antibodies. Any           
loci found to display differences in oxoG enrichment and/or OGG1 occupancy will be             
screened for specific enhancers, promoter regions, or genes documented as          
proto-oncogenic or tumor suppressors. If such differences are found, the impacted           
regions will be investigated during the following aim as to whether or not the gene               
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expression of those parts of the genome has changed at all. Any changes in gene               
expression can be targets for future investigations in supporting OGG1’s potential as a             
therapeutic target.  
Experimental design. 
a. Genome-wide mapping of oxoG using OG-seq 
First, the location and quantity of the oxoG lesion will be mapped using the OG-seq               
method developed by Ding and colleagues.​22 Essentially, OG-seq operates via          
biotinylation and affinity purification, as opposed to the antibody and          
immunoprecipitation (IP) utilized in previous methods. OG-seq has been developed as           
an alternative to those previously established methods of identifying oxoG damage,           
touting two main advantages: high resolution and whole-genome sequencing.  
One promising attribute of OG-seq is the ability to maintain the integrity of the              
sequences containing oxoG at higher resolutions (approximately 0.15-kb resolution).         
Previous studies that used oxoG antibodies yielded genomic maps that were not            
resolute enough to determine precise genomic elements (ie. promoters, UTRs, etc.),           
producing a map at around 1000-kb resolution.​10,22,24,26,27 Additionally, the antibody          
method was hampered by DNA secondary structure, a challenge that OG-seq           
circumvents by labeling oxoG after fragmenting the genomic DNA as opposed to            
introducing oxoG antibodies for IP while the genomic DNA still has its secondary             
structure. The other primary method employed PCR primers to detect a G to T mutation               
that was assumed to be resultant from oxoG damage (following the G:C to T:A mutation               
previously described). During the replicative cycles of PCR, the oxoG damage would            
pair with an A, resulting in a G to T transversion as the sequence is amplified. Thus,                 
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researchers could indicate that an oxoG lesion must have been present at that location              
in the sequence because of this G to T mutation. Unfortunately, this PCR method              
required targeting of specific sequences and was thus limited by low throughput from             
creating a full genome map.  
The original use of the OG-seq method was in mouse embryonic fibroblasts, but this              
experiment will be executed in human lung epithelial cells, both non-cancerous and            
cancerous. OG-seq enables measuring the localization and enrichment of oxoG via the            
chemical labeling of the oxoG lesions using a commercially available amine-terminated           
biotin with a polyethylene glycol (PEG) linker (BTN). BTN is attached to oxoG through a               
one-electron oxidizing agent K​2​IrBr​6 that is sufficiently reactive with oxoG without           
introducing any oxidative damage to the unaffected guanine residues (Figure 3).  
 
Figure 3. Covalent labeling of oxoG with BTN via selective oxidation using K​2​IrBr​6​. Method developed by                




BTN is introduced to the DNA after the genomic material is fragmented into segments of               
around 150 base pairs by sonication. The 150-mers are labeled with the amine adduct              
by incubating them with the oxidant K​2​IrBr​6 and the BTN label.​22 Affinity purification (AP)              
using streptavidin (STP) coated agarose beads will extract the biotinylated strands, then            
the complementary strands will be released from the beads with 150 mM NaOH. The              
eluted strands will then be prepared with a single-stranded DNA adaptor kit before             
submission for Illumina Next Generation Sequencing (NGS) to determine the          
sequences of the enriched elements (Figure 4). We will compare the oxoG enrichment             
of the healthy lung epithelial BEAS-2B cells with the NCI-H1563 and the NCI-H1838             
lung adenocarcinoma cells.   
To control for any    
sequence-dependent biases  
that may occur during the     
sequencing library preparation   
steps, an input control will be      
constructed by fragmenting a    
genome from the BEAS-2B    
cells without BTN labeling.    
Ding and colleagues produced    
an average depth of 3x     
genome coverage from their  
input control. Figure 4. ​Enrichment of oxoG-containing strands from genomic  
DNA using the OG-seq method. ​Adapted from Ding et al.​22 
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Enrichment will be determined relative to the results of the BEAS-2B OG-seq replicates.             
As certain regulatory regions are already established to have a higher incidence of             
oxoG, analysis will be focused on determining differences in prevalence between the            
healthy cells and cancer cells. This is not intended to explicitly confirm the enrichment              
results of previous studies, but to use the developed technology to delve into the              
specifics of that enrichment. Each OG-seq experiment will be performed with three            
replicates and enrichment cutoffs that will determine significant differences in oxoG           
localization will be at peaks of 3-fold enrichment and higher.​22 ​These experiments will             
yield a genome-wide map of oxoG enrichment variation between the lung cancer            
models and the healthy cell line. 
b. Genome-wide mapping of oxoG using enTRAP-seq 
The next method of oxoG mapping will be the enTRAP-seq method recently developed             
by Fang and Zou​23 that replicates the effects of ​in vitro ​borohydride trapping with an               
K249Q mutation in OGG1, followed by affinity purification and sequencing. When OGG1            
interacts with the oxoG damage, it forms a Schiff base intermediate with the oxidized              
ring before excising the base. A common ​in vitro ​method of establishing a stable              
covalent attachment between the enzyme and oxoG lesion is to introduce sodium            
cyanoborohydride (NaBH​3​CN) as a mild reducing agent to trap the enzyme onto the             
DNA strand (Figure 5). Sodium cyanoborohydride is a more optimal reducing agent than             
sodium borohydride (NaBH​4​) because its capacity for reduction limits itself to the bond             
of interest without inducing any off-target reduction in the process. Alternatively, the            
enTRAP-seq method takes advantage of a mutated OGG1 protein. OGG1 Lys249 is            
essential for the glycosylase activity because it attacks the C1′ site of oxoG to form that                
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Schiff base intermediate. Mutating the Lysine residue to Glutamine (K249Q) has been            
reported to block the catalytic activity of the enzyme without compromising substrate            
recognition or specificity, meaning it also retains its ability to recognize the cytosine             
opposite the oxoG base.​23,28 Thus, the K249Q mutant non-covalently binds OGG1 to            
oxoG by rendering OGG1 catalytically inactive. 
 
Figure 5. ​Borohydride trapping assay of oxoG with OGG1. Sodium cyanoborohydride (NaBH​3​CN)            
selectively reduces the positively charged nitrogen of the Schiff base intermediate to form a stable               
covalent connection. The enTRAP-seq method mimics that connection with the K249Q point mutation,             
binding oxoG and OGG1 non-covalently by preventing catalysis. ​Adapted from Fang et al​.​23 
The procedure for enTRAP-seq, established by Fang and colleagues​23​, is relatively           
straightforward (Figure 6). Genomic DNA will be extracted from each cell line and             
fragmented using commercially available digestion methods. In order to prevent any           
further oxidation during the extraction and fragmentation process, desferal         
(deferoxamine) will be added during each step. Once fragmented, the DNA sample will             
be divided into a control group and an experimental group. The control group will be               
treated with Fpg (the bacterial functional analog of OGG1) to excise as much of the               
oxoG present as possible before introducing the K249Q OGG1. This will establish a             
baseline to which the enrichment peaks of the experimental sample can be compared.             
A true enrichment peak from the experimental group must be larger than that of the               
control group, thus preventing false positive peaks from influencing the data analysis.            
After the control treatment, both samples will be treated with the K249Q OGG1,             
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followed by affinity purification and elution of the glycosylase from the DNA samples.             
The resultant DNA will be prepared using Illumina’s commercially available DNA Library            
Prep Kit and then submitted to Illumina for Next Generation Sequencing (NGS) and             
quantification. 
 
Figure 6. ​Scheme of the enTRAP-seq method developed by Fang et al​23 for enrichment of genomic DNA                 
with OGG1 occupancy. NGS results from the control serve to establish the background signal against               
which the level of enrichment for each sequence will be measured. 
This experiment will also be conducted on each cell line, contrasting the oxoG             
enrichment of the healthy lung epithelial BEAS-2B cells with the NCI-H1563 and the             
NCI-H1838 lung adenocarcinoma cells. 
Auxiliary Approaches. In the event that no significant differences are found between the             
healthy and cancerous cell lines, then specific sequences can be targeted in place of              
the genome-wide mapping approach. These new target sequences would be          
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documented regulatory regions of known proto-oncogenes and tumor suppressors. As          
this approach has a more narrow focus and higher resolution than OG-seq and             
enTRAP-seq, it would yield promising results, though limited in scope, as the            
sequencing would be focused on a chosen set of genes instead of the full genome. The                
higher resolution is due to the nature of the PCR sequencing method previously             
described, as the location of the oxidative damage can be more accurately identified via              
this sequencing method. As lung cells are the model of this proposal, genes relevant to               
lung adenocarcinoma will be studied. For example, mutations in the TP53, EGFR, and             
KRAS genes are common in lung cancers and can provide the target genes, promoters,              
and UTRs for this auxiliary approach.​19,29,30 
Expected Results. The OG-seq experiments are expected to provide more than 90            
million reads that will cover the human genome almost three times. Enrichment is             
expected to be found in promoter regions and UTRs, consistent with the findings of              
previous studies.​10,22,23,31 For the purposes of data analysis, promoter regions will be            
defined as 500 bp upstream and 100 bp downstream of the transcription start site and               
UTRs will be defined as beyond that interval.​23 The enTRAP-seq experiments are            
expected to yield on the order of 10,000 significant enrichment peaks, likely in the same               
promoter regions and UTRs found in the OG-seq experiments. OGG1 occupancy is            
expected to be nearly identical to the oxoG enrichment detected by both OG-seq and              
enTRAP-seq, but if we wish to verify this, we can perform a standard ChIP-seq assay               




Differences in quantity and location of oxoG between healthy cells and cancerous cells             
in the results of both experiments would point to an epigenetic and regulatory distinction              
between the cell types. The genes found to be associated with those differences will be               
of particular interest in the analysis of transcription that will be pursued in the second               
aim of this proposal. 
Aim 2: Investigate if oxoG enrichment and OGG1 occupancy are associated with 
the changes in expression level of key genes in both healthy lung 
epithelial cells and lung cancer cells. 
a. Healthy vs cancer  
b. Healthy + inhibition vs cancer + inhibition 
Objective and Overview. This aim is intended to determine if the transcriptional behavior             
of new target genes identified in Aim 1 also differ between healthy lung epithelial cells               
and lung cancer cells. In order to determine if the changes in gene expression that may                
be found are actually dependent on OGG1, the same transcriptional profiling will be             
performed with each cell line exposed to a series of OGG1 inhibitors. The inhibitors that               
will be employed are small molecules that have already been confirmed to be effective              
inhibitors specific to human OGG1 (hOGG1) and serve to replicate an OGG1 knockout             
strain, as there are not OGG1-deficient lung cells currently available. Future           
experiments could develop an OGG1 knockout line using the CRISPR-Cas9 system,           
but that has not yet been done. This proposal will use the following inhibitors: TH5487               
(IC​50 = 342 nM)​21​, SU0268 (IC​50 = 59 nM)​32​, and D0167 (IC​50 = 330 nM)​33 (Figure 7).                 
Performing this experiment with three different inhibitors in parallel will help mitigate            
confounding effects from potential off-target interactions and account for distinct modes           
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of inhibition. The comparison of gene expression will be carried out using Real Time              
quantitative Reverse Transcription PCR (qRT-PCR) to measure the quantity of mRNA           
transcripts for each of the     
target genes in each cell     
line. Analysis will be    
carried out across a 3-by-4     
matrix of experiments,   
comparing the healthy   
cells and cancer cells both     
with and without inhibitors    
(Table 1).     ​Figure 7. ​Structure of each inhibitor with the associated IC​50​ value. 
Table 1. ​Comparison Matrix of Each Cell Line with Each OGG1 Inhibitor 
 
Experimental design. Quantification of the mRNA transcripts in each of the experimental            
scenarios described in Table 1 will be accomplished using Real Time qRT-PCR. Real             
Time qRT-PCR combines the technologies of qPCR and reverse transcription with           
fluorescent probes that deliver quantitative data in real time during the replication            
process of PCR.​34,35 Because the starting material of this reaction will be mRNA             
transcripts after cell lysis and collection, reverse transcription is necessary to develop            
cDNA of the transcripts that can be amplified by PCR. After the cDNA creation, qPCR is                
19 
BEAS-2B (healthy) NCI-H1563 (cancer) NCI-H1838 (cancer) 
BEAS-2B ​+ TH5487 NCI-H1563 ​+ TH5487 NCI-H1838 ​+ TH5487 
BEAS-2B ​+ SU0268 NCI-H1563 ​+ SU0268 NCI-H1838 ​+ SU0268 
BEAS-2B ​+ D0167 NCI-H1563 ​+ D0167 NCI-H1838 ​+ D0167 
 
performed, amplifying and quantifying the amount of each transcript in the sample            
(Figure 8A). Running one-step qRT-PCR (performing reverse transcription and the Real           
Time qPCR at the same time) is the preferred method over the two-step method of               
reverse transcription and qPCR occurring separately, as it eliminates issues of           
experimental variation from the extra step.​34,36 However, because mRNA can be rapidly            
degraded if handled poorly, there will be three independent replicates of each cell             
culture from Table 1 as well as three replicates of each qRT-PCR reaction for each               
individual replicate. This series of replicates should properly safeguard against          
experimental errors as well as inconsistencies in the reaction efficiency of both the             
reverse transcription and qPCR. 
 
Figure 8. ​Real Time qRT-PCR. ​A) ​Conversion of mRNA extracted from the cells into cDNA via reverse                 
transcription and quantification of the library via PCR amplification. ​B) ​Mechanism of the hydrolysis probe               
used for real time quantification. Hydrolysis occurs, releasing the fluorophore, when the DNA polymerase              
passes over the probe during strand extension. 
Real Time qRT-PCR uses the standard components of RT-PCR - dNTPs, primers            
specific to the target transcripts, a reverse transcriptase, and the Taq DNA polymerase             
(Taq DNAP) - and a fluorescent probe. The fluorescent probe is the integral element of               
the real time data collection, pioneered as the TaqMan assay.​35 The fluorescent probe,             
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known as a hydrolysis probe, is a small oligonucleotide (~4 bases long) with a              
fluorophore at the 5’ end and a quencher at the 3’ end (Figure 8B). With such close                 
proximity to the quencher, the fluorophore does not emit a signal when excited by light               
energy input. During the PCR cycles, this probe anneals to the target sequence             
downstream of the primer. As the Taq DNAP constructs the new strand and passes              
over the fluorophore, it releases the fluorophore, enabling a signal to be detected. This              
method is known as ​Fluorescence Resonance Energy Transfer (FRET) and is reviewed            
by Jares-Erijman and colleagues.​37 Because more than one transcript will be quantified            
in a single reaction, multiple probes with distinct sequences and distinct fluorophores            
will be used, depending on the target transcripts. 
Analysis of the data focuses on the curve developed by the increasing fluorescent             
signal. These curves are divided into four phases: the linear ground phase, early             
exponential phase, exponential phase, and plateau phase. Baseline fluorescence is          
calculated during the linear ground phase as fluorescence has not yet risen above the              
background signal. During the early exponential phase, the signal reaches a           
significantly higher level (~10 times the standard deviation) of the background signal.            
The cycle at which this occurs is known as C​t or CP. That value is indicative of the                  
starting number of transcripts in that sample.​34,38 Once the CP value is calculated for              
each transcript across all replicates and experimental conditions, comparisons will be           
made between each series of conditions using an ANOVA for the necessary matrix of              
comparisons to establish significant differences in the expression of the target genes. 
Auxiliary Approaches. If the Real Time qRT-PCR does not yield results indicating            
significant differences in OGG1-mediated gene expression between the healthy and          
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cancer cell lines, another option for quantification is RNA-seq. RNA-seq would provide            
analysis for the entire transcriptome instead of targeting specific sequences. This           
method is a larger undertaking than qRT-PCR and would require much more extensive             
data analysis to glean any conclusions from the data. RNA-seq operates by extracting             
the complete set of mRNA from the cells, reverse transcribing the mRNA into a cDNA               
library, and fragmenting the library using sonication or other forms of digestion. The             
cDNA fragments are then fitted with sequencing adaptors, amplified by PCR, and            
submitted for Illumina NGS. All the sequenced reads are then mapped onto the human              
reference genome and the number of repeat matches on any one gene are quantified to               
determine the level of gene expression.​39,40 The technology for the next generation RNA             
sequencing, quantification, and the subsequent analysis is available through Illumina. 
Expected Results. Considering the data from the Real Time qRT-PCR experiment,           
differential expressed transcripts will be defined as transcripts that have 3-fold or            
greater change from the point of comparison. The healthy uninhibited cells will be             
treated as a general indicator for the baseline, but as the data will be analysed using an                 
ANOVA, each pairing may lead to interesting conclusions. The primary focus will be             
comparing the results of the healthy uninhibited cells to both cancerous uninhibited cell             
lines. If there is a reported difference in the gene expression of the experiment’s target               
genes between the uninhibited cultures, this would indicate a series of notions. As the              
target genes would have been confirmed to be subject to regulation by OGG1             
occupancy in Aim 1, significant results would support the hypothesis that the gene             
expression levels that are unique to the cancer phenotype are in fact associated with              
changes in OGG1 occupancy - OGG1 is present at the regulatory regions of those              
22 
 
genes when the changes in gene expression are induced. In order to further confirm this               
association, the inhibited cultures would necessarily yield opposite results: by removing           
OGG1, the changes in gene expression seen in the uninhibited cultures would be             
non-existent or even reversed. It should be noted that this expectation is reliant on the               
inhibitors interfering with OGG1 binding, not only with catalysis, which is in part why all               
three inhibitors are being used. A lack of this reversion in gene expression could              
indicate that either there is no correlation between the gene expression of the target              
genes and OGG1 occupancy or that there is a biological redundancy that compensates             
for the absence of OGG1. 
D. Future Directions  
Characterizing how oxoG and OGG1 are ingrained in the regulatory web of gene             
expression strengthens the current understanding of their epigenetic role and their           
impact on disease development. Identifying the role oxoG and OGG1 play in the             
regulation of promoters, transcription factors, and mediators associated with cancer          
enables therapeutic development to take advantage of this new insight in order to             
create more effective and more specific treatments. OGG1 has already been           
considered as a target for the development of co-chemotherapeutic treatments and the            
results of this proposal would inform the approach in crafting selective and effective             
interventions. 
This proposal intends to identify specific genes whose expression are impacted by the             
epigenetic marker of oxoG and the resultant localization of OGG1 and to determine the              
role those genes play in cancer cells. As was noted, signaling elements and             
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transcription factors such as TNFɑ and NFκB, respectively, are thought to be            
mechanistically intertwined with OGG1. This relationship is a promising avenue for           
investigation, specifically in whether the oxidative-stress-recruitment model (Figure 2)         
holds merit. To determine a possible correlation with TNFɑ dependency and NFκB            
recruitment via OGG1, one could remove TNFɑ transgenically and expose the cells or             
organism to oxidative stress and measure with both OG-seq and enTRAP-seq how            
oxoG enrichment, and indirectly OGG1 localization, might be affected by those           
changes. The nuclear localization of NFκB could be measured simultaneously to detect            
any effects of the TNFɑ depletion farther downstream. Beyond simply observing NFκB            
localization, studies could be conducted into the expression of those pro-inflammatory           
genes known to rely on NFκB for transcriptional activation. 
Along a different vein, the genes identified in this proposal can be studied more              
extensively. If any of those genes had not previously been associated with the cancer              
phenotype, there are myriads of opportunities to investigate how the altered expression            
of those genes contributes to tumorigenesis. The transcripts and peptide products of            
those genes could additionally serve as new therapeutic targets. The results of this             
proposal can also be replicated in cell types other than human lung tissue. Using other               
cell types could yield transcriptional changes unique to the type of cancer being studied,              
which would further expand the opportunity for more targeted and effective therapeutics.            
This proposal could open multiple new avenues of investigation into the mechanisms            
and associated players of cancer development as well as into the translational field in a               
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